Lab Management
Advances enhance performance of mass spectrometers.
Pharmaceutical companies, healthcare providers, research organizations, universities, and government agencies are continuously under pressure to cut costs due to a generalized economic downturn. This pressure has moved the procurement process to the forefront, with managers looking to achieve better business performance through more effective management of categories, suppliers, and teams.1
The total volume of research at the University of Michigan was $1.31 billion in the fiscal year that closed June 30, 2014, just below the record high of $1.33 billion from the previous year.
This month, we highlight companies that will be exhibiting at two upcoming tradeshows, Experimental Biology 2015 (EB 2015) and the American Association for Cancer Research’s 2015 annual meeting and Exhibit (AACR 2015). EB 2015 will take over the Boston Convention and Exhibition Center in Boston, MA from March 28-April 1. AACR 2015 will be held at the Pennsylvania Convention Center in Philadelphia, PA, from April 18-22, 2015, with exhibit dates April 19-22. Remember that these specific technologies may not be at the show, but their manufacturers will be on hand to answer any questions you may have.
Biofuel producers in Western Canada will soon be able to purify and convert raw glycerol more cost-effectively thanks to an investment of $538,542, announced recently by the Honourable Michelle Rempel, Minister of State for Western Economic Diversification.
INTEGRA has created a short, simple and engaging ‘SimpleShow’ format video to explain the safety features of their FIREBOY Safety Bunsen Burner.
It has been over 40 months since President Obama signed the Leahy-Smith America Invents Act (AIA) into law in September 2011, climaxing years of feverish legislative wrangling. AIA was heralded as a game-changer, the dawning of an equitable intellectual property (IP) regimen that rewarded research scientists and innovators beset by ineffectual patent processes and procedures.
Problem: A variety of factors can result in obsolete laboratory equipment and R&D devices. Project
completion, equipment upgrade, lab closure, and downsizing all create surplus pharmaceutical assets
no longer required in the same capacity—or at all. Given budget restrictions and the importance placed
on environmentally-sound business practices, organizations can’t afford to allow surplus assets to lie
idle or dispose of them without thought to the process. Surplus requires an innovative and sustainable
process that supports strategic business goals.
Problem: Laboratories are faced with challenges when it comes to storing and tracking samples.
The equipment, instruments, and systems introduced to the laboratory market at PITTCON 2015
Likely the most successful company to result from university research innovation was Google. But, when such a startup comes out of a university, which party owns the intellectual property (IP) rights?
